RxDoctor Payments Data

Michael Sinitsa, MD

Family Medicine · Reading, PANPI 1922009307

Payments from drug & device makers

$3,160in general payments, 2019–2025

Across 184 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$596
  • Boehringer Ingelheim$360
  • Pfizer$314
  • AstraZeneca$305
  • GSK$234
  • Lilly USA, LLC$202
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$3,11899%
  • Education$421%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,160 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$172,759
Medicare patients
375
Services billed
1,650

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide66$93,559
JardianceEmpagliflozin85$89,297
EliquisApixaban87$87,163
OzempicSemaglutide61$86,265
TrulicityDulaglutide59$75,792
JanuviaSitagliptin Phosphate49$39,781
FarxigaDapagliflozin Propanediol15$23,526
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$23,520
VascepaIcosapent Ethyl15$15,448
XareltoRivaroxaban12$13,941
Incruse ElliptaUmeclidinium Bromide24$12,406
Atorvastatin Calcium710$8,107
Losartan Potassium413$4,536
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate19$4,044
SynthroidLevothyroxine Sodium60$3,867

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$202$169,351125 claims
Boehringer IngelheimJardiance$360$89,29785 claims
PfizerEliquis$314$87,16387 claims
Novo NordiskOzempic$596$86,26561 claims
MerckJanuvia$160$39,78149 claims
GSKTrelegy Ellipta, Incruse Ellipta$234$35,92637 claims
AstraZenecaFarxiga$305$23,52615 claims
Johnson & JohnsonXarelto$53$13,94112 claims
AbbVieSynthroid$188$3,86760 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Reading

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →